http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112996913-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-077 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0318 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-122 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-072 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-11 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-00 |
| filingDate | 2019-12-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112996913-B |
| titleOfInvention | Oligonucleotide molecules and their applications |
| abstract | Small activating nucleic acid molecules and uses thereof for the treatment of spinal muscular atrophy are provided. The small activating nucleic acid molecule comprises a sense nucleic acid strand and an antisense nucleic acid strand, the sense nucleic acid strand and the antisense nucleic acid strand are oligonucleotide strands with a length of 16-35 nucleotides, respectively, and one of the nucleotide strands is connected to a selected oligonucleotide strand. There is at least 75% base homology or complementarity to the target site in the SMN2 promoter region of the target gene. Also provided is a pharmaceutical composition comprising a small activating nucleic acid molecule and optionally a pharmaceutically acceptable carrier; and using the small activating nucleic acid molecule or a pharmaceutical composition comprising the small activating nucleic acid molecule to upregulate the expression of a target gene in a cell and to treat the expression of the target gene Insufficient approach to disease caused by. |
| priorityDate | 2018-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 90.